Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AstraZeneca hits 2014...

    AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woes

    Written by savita thakur thakur Published On 2016-08-08T12:38:34+05:30  |  Updated On 8 Aug 2016 12:38 PM IST
    AstraZeneca hits 2014 Pfizer bid price, helped by Bristols woes

    London : AstraZeneca shares hit a record high, breaching for the first time the 55 pounds a share level offered by Pfizer in 2014 during the U.S. group's abortive $100 billion attempt to buy the drug maker.


    The British firm's stock has been on a roll recently, helped by a falling pound and speculation that Switzerland's Novartis might be next to launch a bid. However, the shares were lifted to a high of 55.05 pounds by the misfortunes of Bristol-Myers Squibb.


    The failure of Bristol's immunotherapy drug Opdivo to slow disease progression in previously untreated patients with lung cancer as hoped was seen by investors as good news for rivals Merck & Co (MRK.N) and AstraZeneca.


    Analysts at Leerink, Jefferies and Deutsche Bank said the negative result with Opdivo increased the potential market opportunity for AstraZeneca's keenly watched combination of durvalumab and tremelimumab.


    Crucial clinical trial results with durvalumab, both on its own and in combination with tremelimumab, are due next year.


    Chief Executive Pascal Soriot believes AstraZeneca can become a major player in cancer drugs that bolster the immune system. And its ability to carve out billions of dollars in potential sales hinges not only on the effectiveness of its own products but on the competitive profile of rivals.


    Cancer is currently the hottest area of research across the drugs industry and some analysts believe this could make AstraZeneca a takeover target once again, with speculation turning last week to Novartis as a bidder.

    AstraZenecaBristol-Myersimmunotherapy drugMerck & CoNovartisOpdivoPfizer
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok